Table 5.
The Literature-Reported VTE Data on Patients Having PC Treated With CRS + HIPEC.
| Reference | Year | Patient, n | Age, years | Operation Duration, hour | Blood Loss, mL | PCI | CC 0-1, n (%) | VTE, n (%) | DVT, n (%) | PE, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Witkamp et al26 | 2001 | 46 | 56 (34-76) | 10 (5.5-18) | 13,000 (1600-55 000) | NA | NA | NA | NA | 3 (6.5) |
| Verwaal et al4 | 2003 | 48 | 53 (28-69) | 8.1 (5.3-12.8) | 3900 (500-30 000) | NA | 39 (81.3) | NA | NA | 2 (4.2)a |
| Ahmad et al27 | 2004 | 33 | 49 (26-72) | 8.3 (4.1-14.8) | 650 (100-3300) | NA | NA | NA | 1 (3.0) | NA |
| Glehen et al28 | 2004 | 506 | 51 (16-81) | NA | NA | NA | 377 (74.5) | NA | NA | 2 (0.4)b |
| Kusamura et al29 | 2006 | 205 | 52 (22-76) | 8.9 (4.0-22.0) | NA | NA | 182 (88.8) | NA | NA | 1 (0.5) |
| Moran et al30 | 2006 | 100 | 52 (32-74) | NA (3-18) | NA | NA | 65 (65.0) | NA | 5 (5.0) | 4 (4.0) |
| Smeenk et al31 | 2006 | 103 | 57 (30-77) | 9.0 (4.5-18.0) | 8000 (300-55 000) | NA | 87 (84.5) | 10 (9.7)b | NA | NA |
| Hagendoorn et al32 | 2009 | 49 | 55 (40-76) | 7.7 (5.0-11.5) | 1420 (150-5500) | NA | NA | NA | 1 (2.0)c | NA |
| Kerscher et al33 | 2010 | 109 | 54.1d | 6.63 (4-12) | NA | 21.2d | 53 (48.6) | NA | NA | 2 (1.8)b |
| Canda et al34 | 2013 | 115 | 53.4 (20-82) | 6.0 (2.0-12.0) | NA | 14.7 (3-28) | NA | NA | 1 (0.9) | 1 (0.9) |
| Votanopoulos et al35 | 2013 | 925 | NA (11-82) | NA | NA | NA | NA | 26 (2.8)e | 17 (1.8) | 9 (1.0) |
| Wagner et al36 | 2013 | 282 | NA | NA (6.5-12.5) | NA (400-2500) | NA (8-18) | 230 (81.6) | 4 (1.4)b | NA | NA |
| Jimenez et al37 | 2014 | 202 | 53 (25-80) | NA | NA | NA | 170 (84.2) | NA | NA | 5 (2.5)b |
| Konigsrainer et al38 | 2014 | 90 | 55 (18-76) | 7.6 (0.6-17.9) | NA | 20 (3-39) | 62 (68.9) | NA | NA | 7 (7.7) |
| Shen et al39 | 2014 | 27 | 52.2d | NA | NA | NA | NA | 2 (7.4)a | NA | NA |
| Spiliotis et al40 | 2014 | 100 | NA | NA | NA | NA (3-39) | 86 (86.0) | NA | NA | 6 (6.0) |
| Beckert et al41 | 2015 | 381 | 55 (14-77) | 7.6 (0.6-17.9) | NA | 20 (1-39) | 263 (69.0) | 27 (7.1) | 10 (2.6) | 17 (4.5) |
| Coccolini et al42 | 2015 | 54 | 54.5d | 8.85d | NA | 10.1 (1-28) | 54 (100.0) | NA | 1 (1.9)b,e | 1 (1.9)b, e |
| Huang et al25 | 2015 | 800 | 53d | NA | NA | NA (2-31) | 765 (95.6) | 43 (5.4) | NA | NA |
| Lord et al43 | 2015 | 512 | 56 (24-82) | NA | NA | NA | 512 (100.0) | NA | 57 (11.1) | 9 (1.8) |
| Randle et al44 | 2015 | 935 | NA (11-87) | NA (4-25.6) | NA (50-6500) | NA (0-39) | NA | 28 (3.0) | NA | NA |
| Spark et al24 | 2015 | 30 | 53.3d (25-71) | 10.1d | NA | NA | 21 (70.0) | NA | 3 (10.0)b | 2 (6.7) |
| Baumgartner et al45 | 2016 | 247 | 53 (20-86) | 6.7 (3.3-13.3) | 250 (10-4000) | 14 (0-29) | 235 (95.2) | NA | NA | 8 (3.2)f |
| Dagbert et al46 | 2016 | 39 | 58.2d | 5.1d | NA | 15.1d | 38 (97.4) | NA | NA | 5 (12.8)g |
| Martin et al47 | 2016 | 203 | NA | 5.1 (5.1-8.3) h | 300 (200-600)h | NA (6-18) | 173 (85.2) | 14 (6.9) | NA | NA |
| Sargant et al48 | 2016 | 201 | 55 | NA | NA | NA | NA | NA | 10 (5.0)i | 4 (2.0) |
| This study | 2018 | 466 | 55 (10-81) | 10.0 (1.6-19.5) | 600 (0-6100) | 23 (0-39) | 257 (60.1) | 23 (4.9) | 22 (4.7) | 1 (0.2) |
Abbreviations: CC, completeness of cytoreduction; CRS, cytoreductive surgery; DVT, deep vein thrombosis; HIPEC, hyperthermic intraperitoneal chemotherapy; NA, not available; PC, peritoneal carcinomatosis; PCI, peritoneal carcinomatosis index; PE, pulmonary embolism; VTE, venous thromboembolism.
a Within 3 months after surgery.
b Grades 3-5 according to the National Cancer Institute’s Common Toxicity Criteria.
c Grades 2-5.
d Average.
e Within 1 month after surgery.
f Within 2 months after surgery.
g Only for those underwent splenectomy.
h interquartile range.
i Including 2 atrial thromboses.